Clinical Report: Prevalence in Middle-Aged Individuals and Delays in Diagnosis of Anti-LGI1 Encephalitis

Overview

This study highlights the clinical features and diagnostic challenges of anti-LGI1 encephalitis, particularly in middle-aged individuals. Key findings indicate that older age, prolonged diagnostic delays, and elevated antibody titers are associated with unfavorable functional outcomes.

Background

Anti-LGI1 encephalitis is a significant autoimmune condition that primarily affects middle-aged and older adults, often leading to severe neurological impairment. Understanding its clinical presentation and the factors influencing diagnosis and treatment is crucial for improving patient outcomes. The high prevalence of inconclusive initial assessments can result in delays that negatively impact recovery.

Data Highlights

Key Findings

• Seizures were the most common presenting symptom (70%).
• Cognitive dysfunction increased to 95% over the illness duration.
• FBDS were observed in 40% of cases.
• Hyponatremia was present in 70% of patients.
• 40% of individuals had normal cranial MRI results at diagnosis.
• Older age and longer diagnostic delays were linked to unfavorable outcomes.

Clinical Implications

Clinicians should prioritize prompt antibody testing in both serum and CSF to facilitate early diagnosis and treatment of anti-LGI1 encephalitis. Awareness of the common presentation features and the potential for normal initial imaging results is essential to avoid misdiagnosis and ensure timely intervention.

Conclusion

The findings underscore the importance of early recognition and treatment of anti-LGI1 encephalitis to improve long-term functional outcomes. Enhanced diagnostic protocols may reduce delays and optimize patient care.

Related Resources & Content

1. Brain, 2023 -- Identification of New Genetic Risk Factors in LGI1-Antibody Encephalitis: Findings from a Genome-Wide Association Study and Validation Analysis
2. Brain, 2023 -- Activated αβ T and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis
3. Brain, 2023 -- Patterns of Brain Atrophy in Patients with Anti-IgLON5 Encephalitis
4. Acta Neuropathologica, 2023 -- Neuronal pSTAT1 as a Marker of Synaptic Dysfunction in Autoimmune Encephalitis Targeting Intracellular Antigens
5. Frontiers in Neurology, 2025 -- Anti-LGI1 encephalitis: clinical presentation, imaging features, and prognostic analysis
6. Frontiers in Neurology, 2025 -- Long-term outcomes in leucine-rich glioma inactivated-1 autoimmune encephalitis and associated biomarkers of inflammation and neuronal and glial injury
7. Anti-LGI1 autoimmune encephalitis: clinical presentation, imaging features, and prognostic analysis
8. Frontiers | Long-term outcomes in leucine-rich glioma inactivated-1 autoimmune encephalitis and associated biomarkers of inflammation and neuronal and glial injury
9. NXI-2024-100834 1..12